Alzheimer's Imaging Consortium
Saturday, July 13, 2012
Presented by the ISTAART Neuroimaging Professional Interest Area
|
|
| Overview | Continuing Medical Education |
| Target audience | Accreditation statement |
| Learning objectives | Credit designation |
| Schedule & Speakers | Disclosure of conflicts of interest |
| Awards | |
|
|
Gil Rabinovici, Chair, University of California, San Francisco, United States
Christopher Rowe, Chair, Austin Health, Melbourne, Australia
The Alzheimer's Imaging Consortium (AIC) pre-conference will focus on the clinical application and methodological development of neuroimaging (MRI, PET, SPECT, CT and others) to Alzheimer's disease, other dementias and normal brain aging. The meeting will consist of invited speakers, as well as oral and poster presentations from submitted abstracts. Presentations from young scientists and interactive discussion will be encouraged. The world's leading imaging and non-imaging researchers will discuss topics such as:
- Early and differential diagnosis and the proposal for new criteria.
- Tracking progression and evaluating treatments.
- Asymptomatic stages of Alzheimer's and normal brain aging.
- Cognitive and basic neuroscientific studies: animal imaging, imaging and genetics.
- Multi-modality imaging studies and new imaging methods.
- The latest developments on other dementias such as Lewy body disease and vascular diseases.
This event is organized by the ISTAART Neuroimaging Professional Interest Area.
Target audience
All researchers and clinicians involved in the care of or research on individuals with memory or other cognitive complaints, including but not limited to neurologists, psychiatrists, radiologists, geriatricians and neuropsychologists; as well as researchers, industry and regulatory agencies stakeholders; and others involved in the use of imaging techniques in the study of Alzheimer's disease, related disorders and normal aging.
Learning objectives
At the end of this educational activity, attendees should be able to:
- Identify the importance of structural, functional, and amyloid imaging in the study of Alzheimer's disease.
- Explain how technological developments of imaging methods can be leveraged in the scientific understanding, early detection and tracking of Alzheimer's disease and the evaluation of promising treatments.
- Recognize new developments in multi-modality imaging approaches and challenges involved in using these techniques in the scientific study and clinical evaluation of Alzheimer's disease and related disorders.
- Discuss the application of imaging techniques to the basic sciences (animal studies, genetics, pathology, etc.) for the understanding of brain function in health and disease.
Schedule and Speakers
|
|||
8:25 a.m. |
Introductions |
||
8:30-9:45 a.m. |
IC-O1 Imaging Populations at Genetic Risk for Alzheimer's Disease |
||
|
IC-O1-01 Presymptomatic Functional Brain Changes in PS1 E280A Mutation Carriers Compared to Other Biomarkers: Pilot Data From the Alzheimer's Prevention Initiative Biomarker Project | ||
|
| Adam Fleisher, Kewei Chen, Yakeel Quiroz, Laura Jakimovich, Madelyn Gutierrez, Jessica Langbaum, Auttawut Roontiva, Pradeep Thiyyagura, Ji Luo, Xiaofen Liu, Wendy Lee, Napatkamon Ayutyanont, Stephanie Parks, Claudia Munoz, Sonia Moreno, Natalia Acosta-Baena, Margarita Giraldo, Pierre Tariot, Francisco Lopera, Eric Reiman | |
|
IC-O1-02 Are Early Atrophy Patterns in Autosomal Dominant Familial Alzheimer's Disease Gene Dependent? | ||
|
| Kirsi Kinnunen, Natalie Ryan, David Cash, António Bastos Leite, Sarah Finnegan, Manuel Cardoso, Kelvin Leung, Marc Modat, Tammie Benzinger, Clifford Jack, Daniel Marcus, Marcus Raichle, Paul Thompson, John Ringman, Bernardino Ghetti, Stephen Salloway, Reisa Sperling, Peter Schofield, Colin Masters, Richard Mayeux, Ralph Martins, Michael Weiner, Randall Bateman, Alison Goate, Anne Fagan, Nigel Cairns, Virginia Buckles, John Morris, Martin Rossor, Sebastien Ourselin, Nick Fox | |
|
IC-O1-03 Hippocampal Transcriptome-Guided Gene-Gene Interaction of Memory Phenotype in MCI and Alzheimer’s Disease | ||
|
| Jingwen Yan, Sungeun Kim, Kwangsik Nho, Rui Chen, Shannon Risacher, Jason Moore, Andrew Saykin, Li Shen | |
|
IC-O1-04 Reduced Amyloid Deposition and Greater Hypometabolism in APOE-?4–Positive People with Alzheimer’s Disease | ||
|
| Manja Lehmann, Pia Ghosh, Cindee Madison, Anna Karydas, Giovanni Coppola, Bruce Miller, William Jagust, Gil Rabinovici | |
|
IC-O1-05 APOE-e4 is Associated With Increased Hippocampal Atrophy Rates in Alzheimer's Disease | ||
|
| Emily Manning, Josephine Barnes, David Cash, Jonathan Bartlett, Kelvin Leung, Sebastien Ourselin, Nick Fox | |
|
IC-O1-05 APOE-ε4 is Associated With Increased Hippocampal Atrophy Rates in Alzheimer's Disease | ||
|
| Emily Manning, Josephine Barnes, David Cash, Jonathan Bartlett, Kelvin Leung, Sebastien Ourselin, Nick Fox | |
9:45-10:15 a.m. |
PL-01 Brain Imaging in Preclinical Study and Prevention of Alzheimer's Disease? Eric M. Reiman, Banner Alzheimer's Institute, Phoenix, Ariz., United States |
||
10:15–10:30 a.m. |
Break |
||
|
|||
10:30–11 a.m. |
PL-02 Developing a Translational Toolbox for Parkinson Disease: The Parkinson Progression Marker Initiative Kenneth Marek, The Institute for Neurodegenerative Disorders, New Haven, Conn., United States |
||
11a.m.-12:30 p.m. |
IC-02 Normal Aging and Early Detection of Alzheimer's Disease |
||
|
IC-O2-01 How Do We Define Amyloid Positivity in an Asymptomatic Population? Comparison of CSF, Quantitative PET and Clinical PET Examinations | ||
|
| Brian Rubin, Yi Su, Jonathan McConathy, Tyler Blazey, Rosana Ponisio, Jin Weng, Russ Hornbeck, Anne Fagan, Chengjie Xiong, John Morris, Tammie Benzinger | |
|
IC-O2-02 Detecting Cognitive Evidence of Preclinical Alzheimer's Disease | ||
|
| Dorene Rentz, Trey Hedden, Elizabeth Mormino, Rebecca Amariglio, John Becker, Aaron Schultz, Gad Marshall, Reisa Sperling, Keith Johnson | |
|
IC-O2-03 The Effects of Aging on Whole Brain Functional Connectivity | ||
|
| Matthew Brier, Jewell Thomas, Liang Wang, Tammie Benzinger, John Morris, Beau Ances | |
|
IC-O2-04 Association between Regional Task-Free Fmri Synchrony and AD Imaging Biomarkers in Cognitively Normal Subjects | ||
|
| Prashanthi Vemuri, David Thomas Jones, Jeffrey L Gunter, Scott A Przybelski, Brian E Gregg, Mary M Machulda, Mathew L Senjem, Val J. Lowe, David S Knopman, Ronald C Petersen, Clifford R Jack |
|
|
IC-O2-05 Development of White Matter Lesions is Preceded by Changes in Normal-Appearing White Matter | ||
|
| Marius de Groot, Benjamin Verhaaren, Renske de Boer, Stefan Klein, Albert Hofman, Aad van der Lugt, Mohammad Ikram, Wiro Niessen, Meike Vernooij | |
|
IC-O2-06 Perfusion and Structural MRI Correlates of Brain Amyloidosis in Early MCI | ||
|
| Duygu Tosun, Michael Weiner | |
|
|||
12:30-2:30 p.m. |
Lunch and Poster Viewing/Poster Judging | ||
2:30-3:45 p.m. |
IC-O3 Emerging Techniques |
||
|
IC-O3-01 The Centiloid Scale: Standardization of Amyloid Imaging Measures | ||
|
| Christopher Rowe, William Klunk, Robert Koeppe, William Jagust, Michael Pontecorvo, Michael Devous, Marybeth Howlett, Daniel Skovronsky, Keith Johnson, Julie Price, Chet Mathis, Mark Mintun | |
|
IC-O3-02 Plaque-Binding Magnetic Nanoparticles for Early Diagnosis of Alzheimer's Disease by Magnetic Resonance Imaging (MRI) | ||
|
| Kwok Kin Cheng, Larry Baum | |
|
IC-O3-03 The Relationship Between Hippocampal Atrophy and Neuropathology Markers: A 7T MRI Study | ||
|
| Sona Babakchanian, Somme Johanne, Hedieh Honarpisheh, Kristy Hwang, Kristina Biado, Spencer Tung, Andrew Frew, Jeffry Alger, Jonathan Wisco, Stephen Schettler, Chris Zarow, Harry Vinters, Paul Thompson, Liana Apostolova | |
|
IC-O3-04 In-Vivo Characterization of Glutamatergic Vulnerability in Behavioral Variant FTD: An [11C]ABP688 PET/ VBM /DBM Study | ||
|
| Antoine Leuzy, Jared Rowley, Laksanun Cheewakriengkrai, Monica Shin, Seqian Wang, Maxime Parent, Eduardo Zimmer, Marina Dauar, Pedro Rosa-Neto, Serge Gauthier | |
|
IC-O3-05 Task-Free fMRI in Clinical Trials: Selection of Covariates and Numeric Endpoints | ||
|
| Adam Schwarz, Basile Pinsard, Vincent Perlbarg, Yuefeng Lu, Lea Marais, Derek Hill, Jean-Francois Mangin, Adam Schwarz | |
3:45-4:15 p.m. |
Panel Discussion—The Role of Neuroimaging in AD Drug Development: Lessons from Recent Clinical Trials Moderator Panelists |
||
4:15-4:45 p.m. |
Neuroimaging Prize Announcements/Presentations |
||
4:45-5 p.m. |
Best poster and oral announcement |
||
|
|||
Awards
(the application process is now closed)
A limited number of fellowships (in the form of complimentary AIC registration) are available for young researchers who submit an abstract. Awardees will be chosen based on the anonymous reviewers' ratings of their oral or poster abstract and financial need. Additionally, the best oral and poster presentation among this group will be awarded a $500 prize each.
Continuing Medical Education
This activity is jointly sponsored by the Postgraduate Institute for Medicine (PIM) and the Alzheimer's Association.
Scientific sessions are not supported by any commercial entity.
Accreditation statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and the Alzheimer's Association. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of conflicts of interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Spotlight
Registration and housing are now open! Join us to celebrate 25 years of discovery, progress and change at AAIC in Boston, United States, July 13-18, 2013.
Register now.
2013 Imaging Consortium Sponsors |
 |
 |
